Nuevocor
@nuevocor.com
Nuevocor is a IND-stage biotech focused on treating genetic cardiomyopathies by addressing their underlying mechanical defects
Nuevocor's Company Logos
Nuevocor's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#653883
Eminence
101, 56, 131
276, 40, 37
23, 57, 0, 49
#FCFCFC
Alabaster
252, 252, 252
0, 0, 99
0, 0, 0, 1
#263066
Cloud Burst
38, 48, 102
231, 46, 27
63, 53, 0, 60
About Nuevocor
Nuevocor is a groundbreaking biotech brand with a focus on curing LMNA and other genetic cardiomyopathies, along with various cardiac diseases. Their flagship LMNA gene therapy is the result of extensive research into the mechanisms underlying LMNA-associated diseases, made possible by the innovative technologies developed by co-founders Colin Stewart and Brian Burke. The team at Nuevocor includes scientific co-founders Mark Kay and Jianming Jiang, who bring expertise in AAV gene therapy and cardiac disease modeling.
They are well-equipped to develop effective treatments for cardiovascular conditions. The brand's team also comprises esteemed individuals such as Mia Hu, an experienced healthcare investor, and Euan Ashley, a leading medical geneticist and cardiologist at Stanford University. Additionally, they have seasoned investors like Khoo Shih and a distinguished lineup of scientific advisors, including David Russell, a renowned expert in viral gene therapy, and Yin Loon Lee, who has played a significant role in developing Nuevocor's technology.
Overall, Nuevocor is dedicated to pushing the boundaries of biotech and bringing about revolutionary advancements in the field of genetic heart disease treatment
Company type
Privately Held
Year founded
2020
Company size
11-50 employees
